Diagnosis and treatment of heparin-induced thrombocytopenia

Perfusion

Volumn 18, Issue 1, 2003, Pages 47-53

  DeBois, William J ^a   Liu, Junli ^a   Lee, Leonard Y ^a   Girardi, Leonard N ^a   Mack, Charles ^a   Tortolani, Anthony ^a   Krieger, Karl H ^a   Isom, O Wayne ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; DALTEPARIN; DANAPAROID; DIPYRIDAMOLE; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE; RECOMBINANT HIRUDIN; SEROTONIN; THROMBIN INHIBITOR; THROMBOCYTE ANTIBODY; THROMBOCYTE FACTOR 4; TIROFIBAN;

ANTIBODY DETECTION; ANTICOAGULATION; CARDIOPULMONARY BYPASS; CLINICAL FEATURE; COMPLEX FORMATION; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART SURGERY; HUMAN; INCIDENCE; PATHOLOGY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEROTONIN RELEASE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; HEPARIN; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; THROMBOCYTOPENIA;

EID: 0037278864     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1191/0267659103pf637oa     Document Type: Review

References (59)

1. Baglin TP. Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment. J Clin Pathol 2001; 54: 272-74
2. Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001; 113: 886- 90
3. Follis F, Schmidt CA. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg 2000; 70: 2173-81
4. Kleinschmidt S, Seyfert UT. Heparin-associated thrombocytopenia (HAT): still a diagnostic and therapeutical problem in clinical practice. Angiology 1995; 46: 37-44
5. Amiral J, Bridey F, Wolf M et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995; 73: 21-28
6. Amiral J, Wolf M, Fisher A, Boyer-neuman C, Vissac A, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996; 92: 954-59
7. Farner B, Eichler, H, Kroll H, Greimacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001; 85: 950-57
8. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-507
9. Mudaliar JH, Timothy KL, Liem TK, Nichols WK, Spadone DP, Silver D. Lepirudin is a safe and effective anticoagulant for patients with heparin-associated antiplatelet antibodies. J Vasc Surg 2001; 34: 17-20
10. Pifarre R. Anticoagulation hemostasis and blood preservation. In Pifarre R ed. Anonymous cardiovascular surgery. Philadelphia, PA: Hanley & Belfus, 1993: 185-89
11. Ali O. Images in heparin-induced thrombocytopenia. J Thromb Thrombol 2000; 10: s27-s33
12. Hartman AR, Hood RM. Anagnostopoulos CE. Phenomenon of heparin-induced thrombocytopenia associated with skin necrosis. J Vasc Surg 1988; 7: 781-84
13. Silver D, Kapsch DH, Tsoi EK. Heparin-induced thrombocytopenia, thrombosis, and hemorrhage. Ann Surg 1983; 198: 301-306
14. Almeida JI, Coats R, Liem TK, Silver D. Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg 1998; 27: 309-14
15. Chong B. Heparin-induced thrombocytopenia. Br J Haematol 1995; 89: 431-39
16. Ginsberg JA, Crowther MA, White RH, Ortel TL. Anticoagulation therapy. Hematology 2001; 339-57
17. Warkentin TE, Chong BH, Greimacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1-7
18. Walenga J, Jeske W, Wood JJ, Ahmad S, Lewis BE, Bakhos M. Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Semin Hematol 1999; 36 (Suppl I): 22-28
19. Arepally G, Reynolds C, Tomaski A et al. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995; 104: 648-54
20. Walenga J, Jeske W, Fasanella AR, Wood JJ, Ahmad S, Bakhos M. Laboratory diagnosis of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 1999; 5(Suppl 1): s21-s27
21. Izban K, Lietz H, Hoppensteadt DA et al. Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Haemost 1999; 25(Suppl I): 51-56
22. Warkentin TE, Sheppard JAI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-708
23. Lee DH, Warkentin TE, Denomme GA, Hayward CP, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haematol 1996; 95: 724-31
24. Jy W, Mao W, Horstman LL, Valant PA, Ahn YS. A flow cytometric assay of platelet activation marker P-selectin (CD62p) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb Haemost 1999; 82: 1255-99
25. Spencer FA. Heparin-induced thrombocytopenia: patient profiles and clinical manifestations. J Thromb Thrombol 2000; 10: s21-s25
26. Lanuzzi JL Jr., Jang IK. Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. J Thromb Thrombol 1999; 7: 259-64
27. Slocum MM, Adams JG Jr., Teel R, Spadone DP, Silver D. Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome. J Vasc Surg 1996; 23: 839-43
28. Kikta MJ, Keller MP, Humphrey PW, Silver D. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome? Surgery 1993; 114: 705-10
29. Laster J, Elfrink R, Silver D. Reexposure to heparin of patients with heparin-associated antibodies. J Vasc Surg 1989; 9: 677-82
30. Walenga JM, Jeske WP, Wallis DE et al. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. Semin Thromb Hemost 1999; 25(Suppl 1): 77-81
31. Magnani H. Heparin-induced thrombocytopenia: an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70: 554-61
32. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998; 80: 292-97
33. Saxon BR, Black MD, Edgell D, Noel D, Leaker MT. Pediatric heparin-induced thrombocytopenia management with danaparoid (orgaran). Ann Thorac Surg 1999; 68: 1076-78
34. Greinacher A, Volpel H, Janssens U et al. Recombinant hirudin provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73-78
35. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-51
36. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000; 96: 2373-78
37. Moledina M, Chakir M, Gandhi PJ. A synopsis of the clinical uses of argatroban. J Thromb Thrombol 2001; 12: 141-49
38. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994; 72: 1-7
39. Hossmann V, Heiss WD, Bewermeyer H. Antithrombin III deficiency in ischemic stroke. Klin Wochenschr 1983; 61: 617-20
40. Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-43
41. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-29
42. Despotis GJ, Hogue CW, Saleem R et al. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesth Analg 2001; 93: 28-32
43. Frederiksen JW. Cardiopulmonary bypass in human: bypass unfractioned heparin. Ann Thorac Surg 2000; 70: 1434-43
44. Gouault-Heilmann M, Huet Y, Contant G, Payen D, Bloch G, Rapin M. Cardiopulmonary bypass with a low-molecular weight heparin fraction. Lancet 1983; 2: 1374
45. Prifti E, Bonacchi M, Leacche M, Mirald F. Undergoing cardiopulmonary bypass using enoxaparin only during a cardiac transplantation procedure. Eur J Cardiothorac Surg 2000; 17: 760-62
46. Arnoletti JP, Whitman GJR. Heparin-induced thrombocytopenia in coronary bypass surgery. Ann Thorac Surg 1999; 68: 576-78
47. Magnani HN, Boijering RJR. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In Pifarre R ed. New anticoagulants for the cardiovascular patient. Philadelphia, PA: Hanley & Belfus, 1997: 487-500
48. Warkentin TE, Dunn GJ, Cybulsky IJ. Off-pump coronary artery bypass grafting for acute heparin-induced thrombocytopenia. Ann Thorac Surg 2001; 72: 1730-32
49. Zulys VJ, Teasdale SJ, Michel ER. Ancrod as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology 1989; 71: 870-77
50. Robitaille D, Carrier M, Cartier R et al. Successful management strategy for mechanical assistance and heart transplantation in patients suffering from heparin-induced thrombocytopenia type II. J Heart Lung Transplant 2001; 20: 1237-40
51. Latham P, Revelis AF, Joshi GP, DiMaio JM, Jenssen ME. Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. Anesthesiology 2000; 92: 263-66
52. Koster A, Pasic M, Bauer M, Kuppe H, Hetzar R. Hirudin as anticoagulant for cardiopulmonary bypass: importance of preoperative renal function. Ann Thorac Surg 2000; 69: 37-41
53. Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment - an evaluation of native blood and plasma assays. Thromb Haemost 1994; 72: 685-92
54. Potzsch B, Madlener K, Seelig C, Riess CF, Greinache A, Muller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77: 920-25
55. Konkle BA, Bauer TL, Arepally G et al. Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. Ann Thorac Surg 2001; 71: 1920-24
56. Mollison PL, Engelfriet CP, Marcela Contreras. Blood transfusion in clinical medicine, ninth edition. Oxford, UK: Blackwell Scientific, 1993
57. Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombobytopenia. N Engl J Med 2001; 343: 515
58. Selleng S, Lubenow N, Wollert HG, Mullejans B, Greinache A. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. Ann Thorac Surg 2001; 71: 1041-42
59. Koster A, Kukucka M, Bach F et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology 2001; 94: 245-51